Low-dose Cytosine Arabinoside Therapy in a Patient with Myelofibrosis during Transformation to Acute Non-lymphocytic Leukemia
- 24 April 2009
- journal article
- case report
- Published by Wiley in Acta Medica Scandinavica
- Vol. 219 (1) , 129-131
- https://doi.org/10.1111/j.0954-6820.1986.tb03286.x
Abstract
A patient with myelofibrosis transforming into acute non-lymphocytic leukaemia (ANLL) was treated with low doses of cytosine arabinoside (ARA-C). Complete remission was obtained twice without serious toxicity. It is suggested that low-dose ARA-C may be an effective and rather non-toxic therapy in patients with myeloproliferative disorders transforming to ANLL.Keywords
This publication has 7 references indexed in Scilit:
- The effect of low dose Ara‐C in acute non‐lymphoblastic leukaemias and atypical leukaemiaBritish Journal of Haematology, 1984
- Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Annals of Hematology, 1984
- Cytarabine: Low-Dose, High-Dose, No Dose?New England Journal of Medicine, 1983
- Does treatment with ARA-C in low dosage cause differentiation of leukemic cells?Blood, 1983
- Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemiaLeukemia Research, 1983
- Small doses of ARA-C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?British Journal of Haematology, 1982
- MYELOFIBROSIS CLINICAL, HEMATOLOGIC AND PATHOLOGIC STUDY OF 110 PATIENTSThe Lancet Healthy Longevity, 1962